Neuroone Medical Technologies (NMTC) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
17 Jun, 2026Vision and mission
Aims to transform the lives of patients with neurological diseases and chronic pain by providing better solutions.
Focuses on innovative treatments that can significantly improve patient outcomes, such as reducing seizures.
Technology and product platform
Proprietary flexible thin film electrode technology enables both diagnostic and therapeutic applications.
Four FDA 510(k) clearances for products addressing epilepsy, trigeminal neuralgia, and chronic pain.
Only FDA-cleared device using the same SEEG electrode for diagnostics and therapy.
Product portfolio includes Evo Cortical and SEEG electrodes, OneRF Ablation System, and drug delivery systems.
Strategic partnerships
Partnership with Zimmer Biomet includes licensing, distribution, and integration with robotic neurosurgery platforms.
Mayo Clinic collaboration for pre-clinical and clinical research, with key advisory board members from Mayo.
Latest events from Neuroone Medical Technologies
- Transformative neurotechnology enables single-procedure treatments and supports robust growth.NMTC
Planet MicroCap Las Vegas 202617 Jun 2026 - Q2 product revenue up 72% to $2.4M, but low cash and losses raise going concern risks.NMTC
Q2 202618 May 2026 - FDA-cleared thin-film electrode platform drives growth in neurology and pain management markets.NMTC
Corporate presentation12 May 2026 - Innovative thin film technology accelerates growth, partnerships, and global expansion plans.NMTC
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - Innovative electrode platform, strong partnerships, and rapid revenue growth drive expansion.NMTC
Corporate presentation16 Mar 2026 - Guiding for $10.5M+ revenue in 2026, driven by novel devices and expanding partnerships.NMTC
Investor update12 Mar 2026 - Key votes include director elections, a reverse stock split, and equity plan amendment.NMTC
Proxy Filing9 Mar 2026 - Proxy covers director elections, reverse split, equity plan amendment, and auditor ratification.NMTC
Proxy Filing27 Feb 2026 - Q1 2026 saw $2.9M revenue, $1.4M net loss, FDA clearance, and FY26 sales outlook of $10.5M.NMTC
Q1 202617 Feb 2026